Bacil Pharma Ltd. | Stock

Financials

Connect with an

Expert

Personalized investment strategies from leading experts

Equirus Wealth Pvt. Ltd.

AMFI-registered Mutual Fund Distributor

support@equiruswealth.com

CIN: U74995MH2018PTC308551

SEBI Depository Participant

IN-DP-741-2023

SEBI Research Analyst

INH000012342

SEBI Registered Broker

INZ000309137

SEBI Portfolio Manager

INP000007076

AMFI Registered Distributor

ARN-148616

NSE Member Id

90301

BSE Member Id

6805

DPID

97700

Sitemap

Digital Wealth Goals

Overseas Travel

Child Education

Digital Wealth Solutions

Goal Based Investment

Estate Planning

Learning Academy

Private Wealth Goals

Wealth Compounding

Wealth Preservation

Lifestyle Preservation

Children’s Needs

Impact Investing

Legacy Preservation

Private Wealth Solutions

Portfolio Management Services

AIFs & Structured Products

Estate Planning

Offshore Products

Secure Digital Platform

Why Equirus Wealth

Trust and Performance

Best leadership team

Putting clients first

Dedicated wealth managers

Best-in class research team

Solutions beyond investments

Global solutions

Digital Solutions

Resources

Financial Glossary

All Mutual Funds

Legal & Policies

Grievance Redressal Policy

Refund & Cancellation Policy

Fraud Prevention

View All Policies

Regulatory Disclosures

SiteMap

Learning Academy

Calculators

Aging Parents Calculator

CAGR Calculator

Car Loan EMI Calculator

Child Education Calculator

Child Marriage Plan Calculator

Compound Interest Calculator

Custom Goals Calculator

Dream Wedding Calculator

First Car Calculator

First Crore Goal Calculator

Home Goal Calculator

Home Loan EMI Calculator

Inflation Calculator

Irregular Cash flow Calculator

Overseas Vacation Goal Calculator

Personal Loan EMI Calculator

Retirement Plan

Simple Interest Calculator

Single Amount Calculator

SIP Delay Cost Calculator

SIP Growth Calculator

Weighted Average Returns

View All Calculators

Other Links

Client Code Error Policy

Client Referral Policy

Conflict Of Interest Policy

Dormant Account Policy

Investor Grievance Redressal Policy

Internal Auction Policy

Limit Setting Policy

Name of Bank Account

Outsourced Activity Policy

Policy on Prefunded Instrument

SEBI Investor Charter

Surveillance Policy

Client Registration Documents-vernacular language-NSE

Client registration Documents–vernacular language–BSE

Download the Forms

Prohibition of Circulation of Unauthorized News

Investor Complaints

Disclosure of Commission

Report Un-solicited messages - NSE India

Account Opening

Account Closure

Aadhar - PAN linking

CVLKRA Validation

Back Office Login

KRA Validation Guidelines

Process of Client Collateral View

Investor Alert - to read

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

LinkedIn Instagram Twitter Facebook Youtube

Copyright © 2025 Equirus Wealth Private Limited

Bacil Pharma Ltd. | Stock